Molecular mass: 592.76 g/mol PubChem compound: 10257882
Sparsentan is a dual endothelin angiotensin receptor antagonist. It is a single molecule that functions as a high affinity, dual-acting antagonist of both the ETAR and AT1R. Endothelin 1, via ETAR, and angiotensin II, via AT1R, mediate processes that lead to IgAN progression through haemodynamic actions and mesangial cell proliferation, increased expression and activity of proinflammatory and profibrotic mediators, podocyte injury, and oxidative stress. Sparsentan inhibits activation of both ETAR and AT1R and thereby reduces proteinuria and slows the progression of kidney disease.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| C09XX01 | C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09X Other agents acting on the renin-angiotensin system → C09XX Other agents acting on the renin-angiotensin system | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| FILSPARI Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| FILSPARI Film-coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Sparsentan is an active ingredient of these brands:
United States (US)France (FR)Lithuania (LT)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
